|
Market Cap (4-Jul) $17,064,960 (1,393rd) |
Close (30-Jun) $0.012 |
Volume (30-Jun) 5,851,219 |
Shortsold (10-Feb) 98,846 (0.00%) (597th) |
|
52w High $6.00 |
52w Low $0.80 |
P/E - |
EPS -1.79 |
OSL released this announcement to the ASX on 5 November 2020, 9:57. The announcement is marked as price sensitive, and is 2 page(s) in length and 220.13kb in size.
You can view all announcements from OSL and see how they appear on a price chart on the announcements page.
At the date of this announcement, OSL was 0.010% short sold according to ASIC data. It was ranked the 619th most shorted stock on the ASX. It is now ranked as the 597th most shorted stock on the ASX with 0.002% of total shares short sold as of the latest reported data (10 February 2025).
| Other Recent Announcements from OSL | |
|---|---|
| Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer | 30 June 2023, 9:49 |
| Notification of cessation of securities - OSL | 29 June 2023, 17:51 |
| Ethics Committee Approves PANCOSIL Clinical Trial | 5 June 2023, 9:31 |
| OncoSil receives Swiss regulatory approval | 5 November 2020, 9:57 |
| Change of Director's Interest Notice | 29 October 2020, 9:30 |
| Change of Director's Interest Notice | 27 October 2020, 14:42 |
| OncoSil achieves first commercial sale | 22 October 2020, 8:35 |
You must be logged in to post a reply.
OncoSil Medical 